Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the approval of two biosimilars, BILDYOS and BILPREVDA, by the UK Medicines and Healthcare products Regulatory Agency, covering all indications of the original drugs in the UK [1] Group 1: Company Developments - Fuhong Hanlin's stock increased by 4.53%, reaching 64.6 HKD, with a trading volume of 79.4842 million HKD [1] - The UK regulatory approval allows Fuhong Hanlin to commercialize BILDYOS and BILPREVDA, which are part of a broader agreement with Organon for exclusive commercialization rights outside of China [1] - Boyu Capital has increased its stake in Fuhong Hanlin, acquiring 262,500 shares and 80,000 shares on November 6 and November 10, respectively, raising its holding from 5.84% to 7% [1] Group 2: Financial Transactions - Boyu Capital previously invested 21.2673 million HKD to increase its stake from 4.89% to 5.15% on June 18, crossing the 5% threshold for reporting [1]

Core Viewpoint - Fuhong Hanlin (02696) shares have risen over 4% following the approval of two biosimilars, BILDYOS and BILPREVDA, by the UK Medicines and Healthcare products Regulatory Agency [1] Group 1: Company Developments - Fuhong Hanlin's stock price increased by 4.53%, reaching 64.6 HKD, with a trading volume of 79.4842 million HKD [1] - The UK regulatory approval covers all indications for the original drugs [1] - In 2022, Fuhong Hanlin granted Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1] Group 2: Investment Activity - Boyu Capital Investment Management Limited purchased 262,500 shares and 80,000 shares of Fuhong Hanlin on November 6 and November 10, respectively, increasing their stake from 5.84% to 7% [1] - Earlier, on June 18, Boyu Capital had invested 21.2673 million HKD to raise their stake from 4.89% to 5.15%, surpassing the 5% threshold for reporting [1]

Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the approval of its biosimilars BILDYOS and BILPREVDA by the UK Medicines and Healthcare products Regulatory Agency, which now cover all indications previously approved for the original drugs in the UK [1] Group 1: Company Developments - Fuhong Hanlin's stock increased by 4.53%, reaching HKD 64.6, with a trading volume of HKD 79.4842 million [1] - The UK regulatory approval allows Fuhong Hanlin to commercialize BILDYOS and BILPREVDA, which are part of a broader agreement with Organon for exclusive commercialization rights outside of China [1] Group 2: Investment Activity - Boyu Capital has increased its holdings in Fuhong Hanlin, purchasing 262,500 shares and 80,000 shares on November 6 and November 10, respectively, raising its stake from 5.84% to 7% [1] - Earlier in the year, on June 18, Boyu Capital had already invested HKD 21.2673 million to increase its stake from 4.89% to 5.15%, surpassing the 5% threshold for reporting [1]